Alloantibody Responses After Renal Transplant Failure Can Be Better Predicted by Donor–Recipient HLA Amino Acid Sequence and Physicochemical Disparities Than Conventional HLA Matching

American Journal of Transplantation

Volumn 16, Issue 7, 2016, Pages 2139-2147

  Kosmoliaptsis, V ^a   Mallon, D H ^a   Chen, Y ^a   Bolton, E M ^a   Bradley, J A ^a   Taylor, C J ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

alloantibody; alloantigen; histocompatibility; kidney transplantation nephrology; major histocompatibility complex (MHC); organ allocation; retransplantation; translational research science

Indexed keywords

CALCINEURIN INHIBITOR; HLA ANTIBODY; HLA DQ ANTIGEN; HLA DR ANTIGEN; PREDNISOLONE;

ADULT; ALLOIMMUNITY; AMINO ACID SEQUENCE; ANTIBODY SCREENING; ARTICLE; CONTROLLED STUDY; FEMALE; GRAFT FAILURE; HLA MATCHING; HOSPITAL ADMISSION; HUMAN; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; ORGAN DONOR; PHYSICAL CHEMISTRY; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 84976520210     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13707     Document Type: Article

References (26)

1. Kosmoliaptsis V, Gjorgjimajkoska O, Sharples LD, et al. Impact of donor mismatches at individual HLA-A, -B, -C, -DR, and -DQ loci on the development of HLA-specific antibodies in patients listed for repeat renal transplantation. Kidney Int 2014; 50: 540–544.
2. Kosmoliaptsis V, Dafforn TR, Chaudhry AN, Halsall DJ, Bradley JA, Taylor CJ. High-resolution, three-dimensional modeling of human leukocyte antigen class I structure and surface electrostatic potential reveals the molecular basis for alloantibody binding epitopes. Hum Immunol 2011; 72: 1049–1059.
3. Kosmoliaptsis V, Sharples LD, Chaudhry AN, Halsall DJ, Bradley JA, Taylor CJ. Predicting HLA class II alloantigen immunogenicity from the number and physiochemical properties of amino acid polymorphisms. Transplantation 2011; 91: 183–190.
4. Kosmoliaptsis V, Chaudhry AN, Sharples LD, et al. Predicting HLA Class I alloantigen immunogenicity from the number and physiochemical properties of amino acid polymorphisms. Transplantation 2009; 88: 791–798.
5. Duquesnoy RJ. Antibody-reactive epitope determination with HLAMatchmaker and its clinical applications. Tissue Antigens 2011; 77: 525–534.
6. Duquesnoy RJ. A structurally based approach to determine HLA compatibility at the humoral immune level. Hum Immunol 2006; 67: 847–862.
7. Tambur AR, Claas FH. HLA epitopes as viewed by antibodies: What is it all about? Am J Transplant 2015; 15: 1148–1154.
8. Duquesnoy RJ, Askar M. HLAMatchmaker: A molecularly based algorithm for histocompatibility determination. V. Eplet matching for HLA-DR, HLA-DQ, and HLA-DP. Hum Immunol 2007; 68: 12–25.
9. Howell WM, Harmer A, Briggs D, et al. British Society for Histocompatibility & Immunogenetics and British Transplantation Society guidelines for the detection and characterisation of clinically relevant antibodies in allotransplantation. Int J Immunogenet 2010; 37: 435–437.
10. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2013. Available from: http://www.R-project.org/.
11. Lefaucheur C, Viglietti D, Bentlejewski C, et al. IgG donor-specific anti-human HLA antibody subclasses and kidney allograft antibody-mediated injury. J Am Soc Nephrol 2016; 27: 293–304.
12. Lee PC, Zhu L, Terasaki PI, Everly MJ. HLA-specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss. Transplantation 2009; 88: 568–574.
13. Mao Q, Terasaki PI, Cai J, et al. Extremely high association between appearance of HLA antibodies and failure of kidney grafts in a five-year longitudinal study. Am J Transplant 2007; 7: 864–871.
14. Mehra NK, Siddiqui J, Baranwal A, Goswami S, Kaur G. Clinical relevance of antibody development in renal transplantation. Ann N Y Acad Sci 2013; 1283: 30–42.
15. Willicombe M, Brookes P, Sergeant R, et al. De novo DQ donor-specific antibodies are associated with a significant risk of antibody-mediated rejection and transplant glomerulopathy. Transplantation 2012; 94: 172–177.
16. DeVos JM, Gaber AO, Knight RJ, et al. Donor-specific HLA-DQ antibodies may contribute to poor graft outcome after renal transplantation. Kidney Int 2012; 82: 598–604.
17. Wiebe C, Nevins TE, Robiner WN, Thomas W, Matas AJ, Nickerson PW. The synergistic effect of Class II HLA epitope-mismatch and nonadherence on acute rejection and graft survival. Am J Transplant 2015; 15: 2197–2202.
18. Wiebe C, Pochinco D, Blydt-Hansen TD, et al. Class II HLA epitope matching-A strategy to minimize de novo donor-specific antibody development and improve outcomes. Am J Transplant 2013; 13: 3114–3122.
19. Mallon DH, Bradley JA, Winn PJ, Taylor CJ, Kosmoliaptsis V. Three-dimensional structural modelling and calculation of electrostatic potentials of HLA Bw4 and Bw6 epitopes to explain the molecular basis for alloantibody binding: Toward predicting HLA antigenicity and immunogenicity. Transplantation 2015; 99: 385–390.
20. Kosmoliaptsis V, Bradley JA, Peacock S, Chaudhry AN, Taylor CJ. Detection of immunoglobulin G human leukocyte antigen-specific alloantibodies in renal transplant patients using single-antigen-beads is compromised by the presence of immunoglobulin M human leukocyte antigen-specific alloantibodies. Transplantation 2009; 87: 813–820.
21. Schnaidt M, Weinstock C, Jurisic M, Schmid-Horch B, Ender A, Wernet D. HLA antibody specification using single-antigen beads—a technical solution for the prozone effect. Transplantation 2011; 92: 510–515.
22. Tambur AR, Herrera ND, Haarberg KM, et al. Assessing antibody strength: Comparison of MFI, C1q, and titer information. Am J Transplant 2015; 15: 2421–2430.
23. Jolly EC, Key T, Rasheed H, et al. Preformed donor HLA-DP-specific antibodies mediate acute and chronic antibody-mediated rejection following renal transplantation. Am J Transplant 2012; 12: 2845–2848.
24. Tambur AR, Buckingham M, McDonald L, Luo X. Development of donor-specific and non-donor-specific HLA-DP antibodies post-transplant: The role of epitope sharing and epitope matching. Clin Transpl 2006; 399–404.
25. Heidt S, Witvliet MD, Haasnoot GW, Claas FH. The 25th anniversary of the Eurotransplant Acceptable Mismatch program for highly sensitized patients. Transpl Immunol 2015; 33: 51–57.
26. Claas FH, Doxiadis II. Management of the highly sensitized patient. Curr Opin Immunol 2009; 21: 569–572.